FindTrial
Sign In

Impact of injectable contraceptive administration on selected outcome measures

Impact of Injectable contraceptive-Depot Medroxyprogesterone Acetate (DMPA) Administration on selected outcome measures.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/10/046782
Enrollment
150
Registered
2022-10-26
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Control Intervention1: Not Applicable: Not Applicable

Sponsors

Rajalakshmi R
Lead Sponsor
Vinayaka Mission Research Foundation
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Female taking Injectable Contraceptive-DMPA

Exclusion criteria

Exclusion criteria: Undiagnosed Vaginal Or Urinary Tract Bleeding Breast Cancer Poorly Controlled Hypertension Multiple Cardiovascular Risk Factors Sever Hepatic Dysfunction

Design outcomes

Primary

MeasureTime frame
Study finding helps in framing self administration of injectable contraceptive as WHO guidelines 2030 focuses on self-intervention towards reproductive and sexual health.Timepoint: 365 days—

Secondary

MeasureTime frame
In this study it refers to the clinical outcomes determining the condition severity, adherence to injectable contraceptives and response to administration of Depot Medroxyprogesterone Acetate reported in research studies can provide benchmarks that assist in decision making for the policy makers.Timepoint: 1 year—

Countries

India

Contacts

Public ContactRajalakshmi R

Vinayaka Mission Research Foundation, Salem

sasi.v@vmcnpdy.edu.in9486199264

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026